ONK Therapeutics is a leading brand dedicated to optimizing next generation off-the-shelf, optimally engineered NK cell therapies for patients with hematological malignancies and solid tumors. By harnessing the innate biology of NK cells, ONK Therapeutics has developed a unique approach to improve both functionality and cytotoxicity through genetic modifications. Their proprietary platform combines a chimeric antigen receptor (CAR) targeting a known tumor antigen, with a TRAIL variant targeting the death receptor pathway, creating a dual-targeted construct.

This innovative approach has the potential to significantly enhance efficacy and minimize the risk of antigen escape. With a wide range of targets and tumor types, ONK Therapeutics aims to bring significant therapeutic benefits to patients. Founded in 2015, the company is privately held and is based on the groundbreaking NK cell and apoptosis research of its founder Prof M O'Dwyer MD and collaborators at the University of Galway, Ireland